SYNGENE · NSE
Syngene International Limited
₹369.05
-2.93% (-₹11.15)
Prev. close
₹380.2
Volume
24,98,133
Delivery %
68.2%
As of
18 Sept 2026
Price history
Vaishali Parekh · Prabhudas Lilladher · 04 Aug 2026
“Recommends buying Syngene International for intraday trading at ₹402, targeting ₹425, with a stop loss at ₹390.”
Entry ₹402Target ₹425 (+5.7%)Stop ₹390 (-3.0%)R:R 1.9:1Expired undecided · -0.8% since entry
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Recommends buying Syngene International for intraday trading at ₹402, targeting ₹425, with a stop loss at ₹390.” | Vaishali ParekhPrabhudas Lilladher | Syngene International | MISS | ||||
“Recommends buying Syngene International for intraday trading at ₹402, targeting ₹425, with a stop loss at ₹390.” How it resolved: Syngene International fell from ₹410.20 to ₹399.90, a -2.51% move, missing the bullish target of ₹425 (03 Sept 2026) | |||||||
Fundamentals
About Syngene International Limited
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Siddharth Mittal BCom, CA, CPA
Headquarters
Bengaluru
Employees
6,692
Website
syngeneintl.comExchange
View on NSE ↗Key stats
Market cap
₹14,854.38 Cr
P/E ratio (TTM)
67.5
Dividend yield
0.33%
EPS (TTM)
₹5.47
Beta (1Y · daily vs NIFTY 50)
0.83
Beta (5Y · monthly vs NIFTY 50)
1.11
Shares float
17.87 Cr
EPS · quarter ended Jun 2026
₹-0.22
Upcoming earnings
11 Nov 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,184.30 Cr | ₹2,604.20 Cr | ₹3,192.90 Cr | ₹3,488.60 Cr | ₹3,642.40 Cr | ₹3,738.70 Cr | |
| EBITDA | ₹771.40 Cr | ₹818.20 Cr | ₹1,005.30 Cr | ₹1,093.90 Cr | ₹1,145.60 Cr | ₹912.60 Cr |
| ₹404.90 Cr | ₹395.80 Cr | ₹464.40 Cr | ₹510.00 Cr | ₹496.20 Cr | ₹316.70 Cr | |
| Diluted EPS | ₹10.11 | ₹9.82 | ₹11.51 | ₹12.69 | ₹12.34 | ₹7.87 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹5,831.00 Cr | ₹6,151.60 Cr | ₹6,795.90 Cr | ₹7,054.70 Cr | |
| — | — | ₹815.20 Cr | ₹555.20 Cr | ₹577.90 Cr | ₹458.40 Cr | |
| Stockholders' equity | — | — | ₹3,618.00 Cr | ₹4,257.70 Cr | ₹4,726.80 Cr | ₹4,839.10 Cr |
Total assets, Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹701.20 Cr | ₹580.60 Cr | ₹823.50 Cr | ₹1,042.10 Cr | ₹1,167.60 Cr | ₹915.20 Cr | |
| Investing cash flow | ₹-628.10 Cr | ₹-611.50 Cr | ₹-656.40 Cr | ₹-495.60 Cr | ₹-744.70 Cr | ₹-860.40 Cr |
| ₹58.00 Cr | ₹-31.30 Cr | ₹-342.50 Cr | ₹-551.40 Cr | ₹-141.80 Cr | ₹-215.00 Cr | |
| Capital expenditure | ₹-446.50 Cr | ₹-475.50 Cr | ₹-518.30 Cr | ₹-510.80 Cr | ₹-770.10 Cr | ₹-368.20 Cr |
| End cash position | ₹323.30 Cr | ₹261.80 Cr | ₹89.50 Cr | ₹85.70 Cr | ₹367.10 Cr | ₹228.60 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24–Mar 25(2Q) | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.42% | 70.41% | 70.41% | 70.29% | 64.86% | 64.86% | 54.88% | 54.80% | 54.79% | 54.79% | 54.79% | 54.72% | 54.72% | 52.74% | 52.68% | 52.68% | 52.68% | 52.68% | 52.59% |
| Public | 28.72% | 28.87% | 28.91% | 28.89% | 34.65% | 34.67% | 44.66% | 44.60% | 44.72% | 44.89% | 44.90% | 44.85% | 44.94% | 46.97% | 47.00% | 47.01% | 47.02% | 47.03% | 46.98% |
| Employee trusts | 0.86% | 0.72% | 0.68% | 0.83% | 0.49% | 0.47% | 0.46% | 0.60% | 0.48% | 0.32% | 0.31% | 0.43% | 0.34% | 0.29% | 0.31% | 0.30% | 0.29% | 0.29% | 0.43% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Syngene International Limited | ₹15,303.17 Cr | ₹369.05 | 69.5 | 3.16 | 6.5% | 0.09 | +2.8% | -43.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Show all 12
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
25 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Syngene International SYNGENE FY26 Final Dividend Remittance
Syngene International Limited confirmed the remittance of its final dividend of Rs 1.25 per equity share for FY 2025-26 to eligible shareholders. This dividend, representing 12.50% on a face value of Rs 10, was approved at the Annual General Meeting on July 29, 2026. Shareholders as of the June 26, 2026 record date received the payment.
Syngene International invests ₹2.52 crore in Ampin C&I Power Twelve for renewable power acquisition
Business Upturn · 25 days ago